Natural ingredient supplier Sabinsa has announced that its Curcumin C3 Reduct product has received a positive opinion as novel food for use in food supplements in each nation of Great Britain.
The Food Standards Agency (FSA) and Food Standards Scotland (FSS) recognised the safety of Curcumin C3 Reduct for use in food supplements at a maximum daily dose of 140 mg for adults 18 years and older, building on a positive opinion previously issued by the European Food Safety Authority (EFSA) in 2021.
Curcumin C3 Reduct is a standardised tetrahydrocurcuminoid (THC) ingredient derived from turmeric.
It is produced through catalytic hydrogenation of curcuminoids extracted from the rhizomes of Curcuma longa, yielding a purified powder containing 95% tetrahydrocurcuminoids.
Sabinsa said in its announcement that the ingredient demonstrates excellent stability, with a confirmed shelf life of 60 months under ambient conditions.
"This positive opinion represents an important milestone for Curcumin C3 Reduct and underscores Sabinsa's commitment to rigorous science and regulatory transparency," said Dr Shaheen Majeed, Global CEO & Managing Director of Sabinsa.
We are pleased that both the FSA and FSS have concluded that our tetrahydrocurcuminoids ingredient is safe under the proposed conditions of use and we look forward to supporting supplement brands in Great Britain with a fully authorised, well-characterised curcuminoid ingredient.
"Receiving the recognition in Great Britain is a significant achievement for our European operations and reflects the strength of the scientific dossier our team assembled in support of this application," added Dr Umar Jan, President, European Operations, Sabinsa.
The final authorisation will open new opportunities for supplement brands across England, Scotland and Wales to incorporate Curcumin C3 Reduct into their product lines with confidence, backed by the thorough review of both the FSA and FSS.
Sabina added that the positive opinion follows on from a comprehensive safety dossier submitted in 2023, supported by multiple toxicological studies, genotoxicity assessments, compositional analyses and human data.
The FSA and FSS found no issues with allergenicity, genotoxicity, or product stability, concluding that the novel food is not nutritionally disadvantageous at the suggested intake level.